Circulating CD3⁺56⁺ Cell Subset in Pre-diabetes

 

 Buy Article Permissions and Reprints

Abstract

Background:

The CD3⁺56⁺ cells are a small but significant population of T lymphocytes encompassing NKT-like and NKT cells, which may play the essential role at the very early stages of atherosclerotic plaque development. The frequency and activity of CD3⁺56⁺ cells in atherosclerosis-inducing dysglycaemic disease (diabetes type 2 or pre-diabetes) is largely unknown.

Methods:

We analysed CD3⁺56⁺ cell count, granzyme, perforin and annexin V profiles in the peripheral blood from a group of patients with pre-diabetes, with diabetes type 2 and from non-dysglycaemic controls. Measurements were made of fasting glucose levels, HbA₁c, 1,5-anhydroglucitol and lipid profile.

Results:

The mean counts of CD3⁺56⁺ cells were significantly higher in patients with pre-diabetes compared to both patients with diabetes and to control group. There was an increase in the number of CD3⁺56⁺ cells producing granzyme and perforin in pre-diabetic patients compared to other groups, while there were no difference in annexin V⁺ populations within examined groups. It was confirmed that CD3⁺56⁺ cells count is modified by metabolic factors and their parameters, namely HbA₁c and 1,5-anhydroglucitol values.

Conclusion:

It could be stated that the alterations of CD3⁺ 56⁺  cells count in peripheral blood of pre-diabetic and type 2 diabetic patients are related to different grades of carbohydrate deteriorations – postprandial hyperglycaemia and chronic hyperglycaemia.

• References

• 1 ADA – American Diabetes Association . Standards of medical care in diabetes – 2007. Diabetes Care 2007; 30 (Suppl. 01) 4-41
  CrossrefPubMedGoogle Scholar
• 2 Barr EL, Zimmet PZ, Welborn TA et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007; 116: 151-157
  CrossrefPubMedGoogle Scholar
• 3 Berzins SP, Uldrich AP, Pellicci DG et al Parallels and distinctions between T and NKT cell development in the thymus. Immunol Cell Biol 2004; 3: 269-275
  PubMedGoogle Scholar
• 4 Buse JB, Freeman JLR. Serum 1,5-anhydroglucitol (GlycoMarkTM): A short-term glycemic marker. Diabetes Technol Ther 2003; 5: 355-363
  CrossrefPubMedGoogle Scholar
• 5 COPE – Cytokines & Cells Online Pathfinder Encyclopedia Version 31.4 (Spring 2013 Edition) http://www.copewithcytokines.de/ 2013
  PubMed
• 6 Vanderlaan PA, Reardon CA. Thematic review series: the immune system and atherogenesis. The unusual suspects: an overview of the minor leukocyte populations in atherosclerosis. J Lipid Res 2005; 5: 829-838
  PubMedGoogle Scholar
• 7 Dworacka M, Szczawińska K, Winiarska H et al. The application of enzymatic method for 1,5-anhydro-D-glucitol estimation in plasma. Diag Lab 1997; 33: 269-276
  PubMedGoogle Scholar
• 8 Dworacka M, Winiarska H. The application of plasma 1,5-anhydro-D-glucitol (1,5-AG) for monitoring type 2 diabetic patients. Dis Markers 2005; 21: 127-132
  CrossrefPubMedGoogle Scholar
• 9 ESC/EASD – European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) . Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 1: 88-136
  PubMedGoogle Scholar
• 10 Frostegård J. Immunity, atherosclerosis and cardiovascular disease. BMC Med 2013; 11: 117 DOI: 10.1186/1741-7015-11-117.
  CrossrefPubMedGoogle Scholar
• 11 Godfrey DI, MacDonald HR, Kronenberg M et al. NKT cells: what’s in a name?. Nat Rev Immunol 2004; 4: 231-237
  CrossrefPubMedGoogle Scholar
• 12 Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol 2010; 11: 197-206
  CrossrefPubMedGoogle Scholar
• 13 Guo H, Xu B, Gao L et al. High frequency of activated natural killer and natural killer T-cells in patients with new onset of type 2 diabetes mellitus. Exp Biol Med (Maywood) 2012; 237: 556-562
  CrossrefPubMedGoogle Scholar
• 14 Hu FB. The impact of diabetes and prediabetes on risk of cardiovascular disease and mortality. Drugs Today (Barc). 2002. 38. 769-775
  Google Scholar
• 15 Kyriakakis E, Cavallari M, Andert J et al Invariant natural killer T cells: linking inflammation and neovascularization in human atherosclerosis. Eur J Immunol 2010; 40: 3268-3279
  CrossrefPubMedGoogle Scholar
• 16 Lee ET, Keen H, Bennett PH et al. Follow-up of the WHO Multinational Study of Vascular Disease in Diabetes: general description and morbidity. Diabetologia 2001; 44: S3-S13
  CrossrefPubMedGoogle Scholar
• 17 Lorenzo C, Williams K, Hunt KJ et al. The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization Definitions of the Metabolic Syndrome as Predictors of Incident Cardiovascular Disease and Diabetes. Diabetes Care 2007; 30: 8-13
  CrossrefPubMedGoogle Scholar
• 18 Major AS, Wilson MT, McCaleb JL et al Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2004; 12: 2351-2357
  PubMedGoogle Scholar
• 19 Nakajima T, Goek O, Zhang X et al. De novo expression of killer immunoglobulin-like receptors and signaling proteins regulates the cytotoxic function of CD4 T cells in acute coronary syndromes. Circ Res 2003; 93: 106-113
  CrossrefPubMedGoogle Scholar
• 20 Solymoss BC, Bourassa MG, Campeau L et al. Incidence, coronary risk profile and angiographic characteristics of prediabetic and diabetic patients in a population with ischemic heart disease. Can J Cardiol 2003; 10: 1155-1160
  PubMedGoogle Scholar
• 21 Takahashi HK, Mori S, Wake H et al. Advanced glycation end products subspecies-selectively induce adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 2009; 330: 89-98
  CrossrefPubMedGoogle Scholar
• 22 Temelkova-Kurkutschiev TS, Kohler T. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000; 23: 1830-1834
  CrossrefPubMedGoogle Scholar
• 23 The DECODE Study Group on behalf of the European Diabetes Epidemiology Group . Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405
  CrossrefPubMedGoogle Scholar
• 24 Weykamp C, John WG, Mosca A et al The IFCC Reference Measurement System for HbA1c: A 6-Year Progress Report. Clin Chem 2008; 54: 240-248
  CrossrefPubMedGoogle Scholar
• 25 Woollard KJ. Immunological aspects of atherosclerosis. Clin Sci (Lond) 2013; 125: 221-235
  CrossrefPubMedGoogle Scholar
• 26 Wu L, Van Kaer L. Natural killer T cells in health and disease. Front Biosci (Schol Ed) 2011; 3: 236-251
  CrossrefPubMedGoogle Scholar
• 27 Yamanouchi T, Tachibana Y, Akanuma H et al. Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body. Am J Physiol 1992; 263: 268-273
  PubMedGoogle Scholar